# WST — West Pharmaceutical Services · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** WST  
**Sources:** 20  
**Published:** 2026-10-03  
**Canonical:** https://app.k3vl4r.com/research/deep-research-wst-west-pharmaceutical-services-catalysts-narrative-ris-5934

---

# West Pharmaceutical Services (WST) — Research Snapshot as of 2026-10-03

## Recent Catalysts (last ~1–3 months)

**Portfolio divestiture — SmartDose 3.5mL sale to AbbVie:** West completed the sale and transfer of manufacturing and supply rights for its SmartDose 3.5mL On-Body Delivery System (and associated facilities) to AbbVie, following a $112.5 million sale agreement first announced in January 2026, subject to working-capital and other adjustments. Management framed the move as a strategic refocus toward higher-growth, large-volume on-body drug delivery technologies, noting the divested platform contributed only ~4% of fiscal 2025 revenues. West will continue developing its other SmartDose platforms, including the 10mL system [[1]](https://finance.yahoo.com/healthcare/articles/wst-completes-smartdose-sale-abbvie-125600049.html).

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-wst-west-pharmaceutical-services-catalysts-narrative-ris-5934 (free to sign up)._
